pumosetrag has been researched along with Colitis, Mucous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, NM; Brady, CA; Butler, AS; Choo, SH; Cioffi, CL; Cohen, ML; Dobritsa, S; Earley, WG; Fitzpatrick, K; Guo, C; Guzzo, PR; Hassler, C; Manning, DD; Masih, L; Naginskaya, J; Ryan, KN; Sikkander, MI; Usyatinsky, A; Wierschke, JD; Zhang, Z | 1 |
| Evangelista, S | 1 |
1 review(s) available for pumosetrag and Colitis, Mucous
| Article | Year |
|---|---|
Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
Topics: Animals; Dopamine Agents; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Treatment Outcome | 2007 |
1 other study(ies) available for pumosetrag and Colitis, Mucous
| Article | Year |
|---|---|
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Mice; Microsomes, Liver; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists | 2011 |